The efficacy of different nutritional formulas of lutein, zeaxanthin, and meso-zeaxanthin and their impact on the human body

| Submission date | Recruitment status No longer recruiting | Prospectively registered | |
|---------------------------|--|-----------------------------|--|
| 14/07/2020 | | [_] Protocol | |
| Registration date | Overall study status | Statistical analysis plan | |
| 30/07/2020 | Completed | [X] Results | |
| Last Edited 25/08/2020 | Condition category Nutritional, Metabolic, Endocrine | Individual participant data | |

Plain English summary of protocol

Background and study aims

Macular carotenoids are important nutrients that accumulate inside the eye, in the centre of the retina (macula). They have an important role in preserving vision since they protect against lightinduced oxidative damage and can improve visual performance. Macular carotenoids have also been found in other areas of the body, like the brain. Studies have also shown they can improve certain cognitive domains such as memory, and they have been used as antioxidants in cardiometabolic diseases (i.e. heart attack, atherosclerosis, etc). Macular carotenoids are dietary of origin, which means that the human body cannot make them and their only source is from certain fruits and vegetables. The supplements used in this study are considered a major source of them, since they contain natural extracts of macular carotenoids obtained from marigolds. The aim of this study is to investigate the impact on the human body of different carotenoid formulations in nutritional supplements by measuring response in serum (blood) concentrations, as well as change in macular pigment, visual function, cognitive function, and metabolism.

Who can participate?

Healthy volunteers, between 18 and 60 years old

What does the study involve?

Participants are asked to take either a supplement containing the macular carotenoids with or without fish oil, or a placebo (dummy tablet) on a daily basis for 6 months; participants are assigned to one of six different groups and neither the participants nor the investigators will know if they are consuming the supplement or the placebo until the end of the study. Each participant will attend the Nutrition Research Centre Ireland, Waterford Institute of Technology, West Campus, Carriganore, Waterford, for three study visits over a 6-month period. There are two main visits, at the start (first visit) and at the end (last visit) of the trial, and a short visit at month 3 only for a fasting blood sample. The main visits last about 2 hours 30 minutes, whereas the study visit for blood samples lasts no more than 10 minutes.

What are the possible benefits and risks of participating? The researchers draw a fasting blood sample and perform ocular dilation in one eye; however, no risks to participants are foreseen. Participation in this study is not a substitute for standard medical care or eye care. It is anticipated that society will benefit from this study. At the end of the study, the researchers will provide a full report on the evaluations performed to you. The participant will be given feedback and gain knowledge on their vision status, cognitive evaluation and macular pigment levels as well as nutritional information and general health recommendations. They will be informed on their macular pigment, which is of note as research has suggested that a person's macular pigment level is a good indicator of overall eye health and brain function.

Where is the study run from? Waterford Institute of Technology (Ireland)

When is the study starting and how long is it expected to run for? April 2017 to December 2018

Who is funding the study? Waterford Institute of Technology Co-Fund Scholarship: Nutrition Research Centre Ireland, Waterford Institute of Technology and Enterprise Partner: Industrial Organica (Mexico)

Who is the main contact? 1. Dr Marina Green +353 (0) 51306261 2. Prof. John Nolan jmnolan@wit.ie

Contact information

Type(s) Scientific

Contact name Prof John Nolan

ORCID ID http://orcid.org/0000-0002-5503-7084

Contact details

Waterford Institute of Technology Carriganore House WIT West Campus Carriganore Waterford Ireland X91 K236 +353 (0)51 834074 jmnolan@wit.ie

Type(s)

Public

Contact name

Dr Marina Green

ORCID ID http://orcid.org/0000-0002-3324-244X

Contact details Waterford Institute of Technology Carriganore House WIT West Campus Carriganore Waterford Ireland X91K236 +353 (0)51 306261 mgreen@wit.ie

Additional identifiers

EudraCT/CTIS number Nil known

IRAS number

ClinicalTrials.gov number Nil known

Secondary identifying numbers Nil known

Study information

Scientific Title

The impact of formulation on lutein, zeaxanthin, and meso-zeaxanthin bioavailability: a randomized double-blind placebo-controlled study

Acronym COAST (the Carotenoid-Omega bio-Availability STudy)

Study objectives

The hypotheses were (a) that the active intervention groups (unrelated treatments) would all have a higher average response, after 6 months, in serum and in tissue concentrations compared with the placebo group, and (b) that the diacetate intervention would have a higher average response as compared with the other three active intervention groups.

Ethics approval required

Old ethics approval format

Ethics approval(s)

1. Approved 26/05/2017, Research Ethics Committee of Waterford Institute of Technology (Waterford, Ireland; +353 (0)51 302000; ethics@wit.ie), ref: 17/HS-MPRG/01

2. Approved 24/05/2017, Research Ethics Committee of the HSE, South Eastern Area (Waterford Regional Hospital, Waterford, Ireland; +353 (0)51 842026; caroline.lamb2@hse.ie), ref: not provided

Study design

Six-arm intervention study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s) Other

Study type(s)

Other

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet

Health condition(s) or problem(s) studied

The impact of formulation on lutein, zeaxanthin, and meso-zeaxanthin bioavailability in a healthy Irish adult sample

Interventions

Participants were blocked randomized, with equal probability and separately for men and women, to one of five active intervention groups, or to a placebo group. Block randomization was performed using a trial management system, "Trial Controller", designed by the research group. Participants take on a daily basis for 6 months:

Group 1: lutein (L) (10 mg) + meso-zeaxanthin (MZ) (10 mg) + zeaxanthin (Z) (2 mg) provided in one capsule Group 2: L (10 mg) + MZ (10 mg) + Z (2 mg) provided in two capsules Group 3: L (10 mg) + MZ (10 mg) + Z (2 mg) provided in DHA/EPA (430 mg/ 90 mg) in two capsules Group 4: L (10 mg) + MZ (10 mg) + Z (2 mg) diacetates provided in micromicellar formulation in one capsule Group 5: L (5 mg lutein) = MZ (15 mg) + Z (1 mg) provided in 1 g of fish oil in two capsules Group 6: placebo (sunflower oil)

Neither the participants nor the investigators will know if they are consuming the supplement or the placebo until the end of the study.

Each volunteer will attend the Nutrition Research Centre Ireland, Waterford Institute of Technology, West Campus, Carriganore, Waterford, for three study visits over a 6-month period. There are two main visits, at the start (first visit) and at the end (last visit) of the trial, and a short visit at month 3 only for a fasting blood sample. The main visits last approximately 2 h 30 min, whereas the study visit for blood samples lasts no more than 10 minutes.

Intervention Type

Supplement

Primary outcome measure

Lutein, zeaxanthin, and meso-zeaxanthin bioavailability measured in serum, macular pigment, and skin using high-performance liquid chromatography (HPLC), the Spectralis investigational macular pigment optical density (MPOD) module, and the Nu Skin Pharmanex S3 scanner, respectively, at baseline and 6 months

Secondary outcome measures

1. Serum lipid concentrations measured from a blood sample using mass spectrometry at baseline and 6 months

2. DHA and EPA measured from a blood sample using gas chromatography at baseline and 6 months

3. Visual function measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) logarithm of the minimum angle of resolution (LogMAR) chart (Test Chart 2000 PROTM) for Bestcorrected visual acuity (BCVA); the LogMAR EDTRS (Test Chart 2000 PROTM) for Letter Contrast Sensitivity (CS); the "Advanced Vision and Optometric Tests" (AVOT) for visual acuity, contrast sensitivity, cone and rod vision; at baseline and 6 months

4. Cognitive function measured using tests of attention, memory, executive function and decision making from the Cambridge Neuropsychological Test Automated Battery (CANTAB, Cambridge Cognition, UK) at baseline and 6 months

5. Medical information obtained through a questionnaire and physical examination at baseline and 6 months

Overall study start date

01/04/2017

Completion date

19/12/2018

Eligibility

Key inclusion criteria

Healthy adults
Age group between 18 and 65 years

Participant type(s) Healthy volunteer

Age group Adult

Lower age limit 18 Years

Sex Both

Target number of participants

Total final enrolment 97

Key exclusion criteria 1. A medical diagnosis of a critical or acute medical condition 2. Intake of nutritional supplements containing lutein, zeaxanthin, meso-zeaxanthin or omega-3 fatty acids

Date of first enrolment 01/09/2017

Date of final enrolment 03/07/2018

Locations

Countries of recruitment Ireland

Study participating centre Nutrition Research Centre Ireland Waterford Institute of Technology, West Campus Waterford Ireland X91K236

Sponsor information

Organisation Waterford Institute of Technology

Sponsor details Nutrition Research Centre Ireland Carriganore House West Campus Waterford Ireland X91K236 +353 (0)51 845505 info@mprg.ie

Sponsor type University/education

96

Website http://www.wit.ie

Funder(s)

Funder type Industry

Funder Name Industrial Organica

Funder Name Waterford Institute of Technology

Results and Publications

Publication and dissemination plan

Primary outcomes will be published in an initial publication in a high-impact peer-reviewed journal, followed by subsequent publications focused on secondary outcomes.

Intention to publish date

31/08/2020

Individual participant data (IPD) sharing plan

The data-sharing plans for the current study are unknown and will be made available at a later date.

IPD sharing plan summary

Data sharing statement to be made available at a later date

| Study outputs | | | | | |
|-----------------|---------|--------------|------------|----------------|-----------------|
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
| Results article | results | 18/08/2020 | 25/08/2020 | Yes | No |